C.H. Robinson Worldwide reported Q2 results on July 29 and the market's reaction was swift and severe — the stock lost nearly 19% on the week to close at $169.34, a move that dwarfs anything seen across its freight peer group and reframes the entire debate around the stock.
The analyst response following the print tells the clearest story. TD Cowen's Jason Seidl cut his price target from $200 to $155 on July 28 — the most bearish reaction among recent updates — while Baird trimmed from $230 to $200 but kept its Outperform rating. That split captures the broader Street dynamic: bulls are scaling back but not abandoning the thesis, while the more cautious voices are pulling targets toward or below where the stock now trades. The consensus mean sits at $200, roughly 18% above the current price, but that figure is being eroded in real time. Earlier in July, before the print, the Street had been moving the other way — Stifel, Susquehanna, and Citizens all raised targets in the $210–235 range around the July 14–15 window. Morgan Stanley remains an outlier, holding an Underweight with a $91 target — a reading so far below the current price that it warrants treating as a structural bear case rather than a near-term call. Against this backdrop, the valuation multiples have compressed sharply: the price-to-earnings ratio has dropped nearly 5.6 turns over the past week to 24.5x, and price-to-book has fallen 2.3 turns to 10.2x, both reflecting the drawdown rather than any change in underlying estimates.
Positioning, by contrast, tells a calmer story than the price action suggests. Short interest has continued the covering trend that predated the print — it now stands at 4.9% of the free float, down from roughly 6.4% at its mid-July peak and off nearly 20% over the past month. Short sellers were exiting before the results, not piling in. The lending market is entirely relaxed: borrow availability has actually loosened further to 908% from 835% a week ago, meaning there are roughly nine shares available to lend for every one currently borrowed. Cost to borrow is just 0.51%, near the low end of its monthly range. The ORTEX short score has drifted down to 41.6 from 48.6 two weeks ago. None of this reads as a short thesis gathering momentum — if anything, the shorts covered ahead of a print that proved them right on price.
Options traders were equally unconcerned going into the release. The put/call ratio edged up to 0.36 on July 28, fractionally above its 20-day average of 0.35 and just half a standard deviation above the mean. There was no hedging surge, no demand for downside protection, no options signal that flagged the move coming. The 52-week high on the PCR is 0.50 — Tuesday's reading is nowhere near it. The market simply did not see the size of the drop coming, which makes the price gap more unsettling, not less.
The insider picture adds one note of context. The CEO sold $2.1 million of stock in late June at $180 and the CFO sold nearly $900,000 in early July at $191 — both well above where the stock now trades. Those disposals were flagged with low significance scores and may reflect routine program selling, but the timing is uncomfortable in hindsight. The net 90-day insider position is a modest 17,595 shares purchased, largely explained by a cluster of small open-market buys in February at prices near current levels.
The question now is whether the $169 level — close to where several insiders bought in February and not far below some newly reduced analyst targets — starts to attract fresh institutional interest, or whether the earnings reaction triggers a broader reassessment of the freight recovery thesis that underpinned the mid-July target upgrades.
See the live data behind this article on ORTEX.
Open CHRW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
